Roche FDA accepts Lunsumio-Polivy lymphoma sBLA
Roche (OTCQX:RHHBY) reported that the FDA has accepted a supplemental Biologics License Application…
EHA26: AstraZeneca battles Roche in untreated follicular lymphoma
At the 2026 European Hematological Association (EHA) conference, held in Stockholm on 11–14 June, AstraZeneca shared preliminary safety…
Health Canada Approves Roche’s Columvi® (glofitamab) as the First Bispecific Antibody in Canada for Relapsed or Refractory Diffuse Large B-Cell Lymphoma after Initial Therapy
DLBCL is an aggressive cancer with a high risk of progression meaning urgent and effective treatments are needed…
Roche: Lunsumio combo hits 87.0% CR in follicular lymphoma
Roche (OTCQX: RHHBY) presented data at ASH 2025 showing Lunsumio (mosunetuzumab) combinations may…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth](https://www.europesays.com/ch/wp-content/uploads/2026/02/84b0110bbf60eb8397db0461bc3549c4-380x220.png)
European Commission approves Roche’s Lunsumio subcutaneous for relapsed or refractory follicular lymphoma
F. Hoffmann-La Roche Ltd Lunsumio provides high rates of deep and long-lasting responses in third-line and later follicular…
Roche to Present 46 Abstracts, 12 Orals at ASH Meeting
Roche (OTCQX: RHHBY) will present 46 abstracts, including 12 oral presentations, at ASH…